SOD2 and cardiovascular disorder: While this latter finding echoes the challenges faced by numerous previous investigators aiming to leverage antioxidant therapies to treat cardiovascular diseases (44, 45), it is possible that specific subtypes of patients [e.g., those with loss-of-function mutations in MnSOD (46)] may benefit significantly from targeted antioxidant therapy.